LINC01123 facilitates proliferation, invasion and chemoresistance of colon cancer cells

Abstract

Colon cancer is one of the major causes of cancer-related death worldwide. Long non-coding RNA (lncRNA) LINC01123 has been suggested to act as an oncogene in non-small cell lung cancer and a prognostic signature in head and neck squamous cell carcinoma. However, its role in colon cancer remains obscure. From TCGA database, LINC01123 was observed to be upregulated in colon adenocarcinoma. Subsequently, the upregulated LINC01123 was also detected in colon cancer cells. Functionally, LINC01123 could enhance cell proliferation, migration, invasion and angiogenesis. Moreover, the chemoresistance of colon cancer cells was verified to be promoted by LINC01123. Afterwards, LINC01123 was found to bind with Ago2 and miR-34c-5p. Besides, miR-34c-5p was confirmed to inhibit the cellular process and chemoresistance of colon cancer cells. Then, VEGFA was disclosed to coexist with LINC01123 and miR-34c-5p in RNA-induced silencing complex. And TCGA database suggested that its expression was correlated with different stages of colon adenocarcinoma. Moreover, it was uncovered that VEGFA could bind with miR-34c-5p and its expression positively correlated with LINC01123 expression. Finally, LINC01123 was proofed to regulate colon cancer progression and cells chemoresistance via VEGFA. In conclusion, LINC01123/miR-34c-5p/VEGFA axis promotes colon cancer malignancy and cells chemoresistance.

Knockdown of LINC01123 inhibits cell viability, migration and invasion via miR‑361‑3p/TSPAN1 targeting in cervical cancer

“…LINC01123 is a lncRNA activated by c-Myc, which exerts oncogenic effects in certain types of cancer. Previous studies show that LINC01123 is upregulated in colon cancer (9), NSCLC (10) and triple-negative breast cancer (22). In the present study, LINC01123 expression was also increased in CC tissue samples and cell lines, suggesting its association with CC development.…”

“…Recently, long intergenic non-protein coding RNA 1123 (LINC01123) has been reported to exhibit a carcinogenic function in certain types of cancer. For example, LINC01123 enhances cell growth, migration, and angiogenesis in colon cancer cells and promotes the progression of colon cancer (9). LINC01123 promotes proliferation and metabolic rewiring in non-small cell lung cancer (NSCLC) cells and promotes tumor growth in vivo (10).…”

Potential Role of miRNAs in the Acquisition of Chemoresistance in Neuroblastoma

“…Down-regulated in MYCN-amplified NB [22,29] and in chemoresistant NB [13] Down-regulated in cervical [30], breast [31,32] gastric [32,33], and lung [34] cancer, osteosarcoma [35], and mesothelioma [36] miR-19b 7.75 Up-regulated in chemoresistant NB [37] Down-regulated in breast [38] and colon [39] cancer and leukemia [40] miR-26b 47.87 Not evaluated Down-regulated in chemoresistant colorectal [41], gastric [42], laryngeal [43], and hepatocellular carcinoma [44,45] cancer and in glioma [46] [48], breast [49], and gastric cancer [50] miR-29c 9.27 Not evaluated Down-regulated in ovarian [51], endometrial [52], gastric [53], and small cell lung [54] cancer, glioma [55,56], and leukemia [57,58] miR-34c 7.49 Not evaluated Down-regulated in colon [59], gastric [60,61], and ovarian [62,63] cancer, and osteosarcoma [64] miR-126a 9.66 Not evaluated Down-regulated in colorectal [65] and breast cancer [66] and in renal cell carcinoma [67] miR-218 12.30…”

“…In detail, miR-27b and miR-16-1 expression levels were found to be reduced by 33.1 and 23.5 fold, respectively, and miR-218 expression was diminished by 9.09 fold, while miR-15a, miR-126, and miR-19b were down-regulated (slightly, but significantly) by 2.8, 2.7, and 1.73 fold, respectively. [59], gastric [60,61], and ovarian [62,63] cancer, and osteosarcoma [64] miR-126a 9.66 Not evaluated Down-regulated in colorectal [65] and breast cancer [66] and in renal cell carcinoma [67] miR-218 12.30 Up-regulated in MYCN-amplified and in metastatic NB [68][69][70] Down-regulated in glioma cells [71], colorectal [72], gallbladder [73], bladder [74], and lung cancer [75,76] miR-338 15.99 Down-regulated in resistant NB [77,78] Down-regulated in esophageal squamous carcinoma cells [79] miR-497 6.92…”

GWAS Links New Variant in Long Non-Coding RNA LINC02006 with Colorectal Cancer Susceptibility

“…Both LINC01354 and lncRNA CASC11 are upregulated in CRC and contribute to the pro-liferation, invasion, and metastasis of CRC via activation of the Wnt/β-catenin signaling pathway [69,70]. Additionally, LINC01123 was upregulated in CRC tumors and cells, and its expression positively correlated with the vascular endothelial growth factor A (VEGFA) expression and the binding of miR-34c-5p, sponged by LINC01123 [71]. The silencing of UNC5B-AS1, highly expressed in CRC tissues, repressed cancer growth and metastasis, most likely by increasing miR-622 expression and suppression of the AMP-activated protein kinase (AMPK) and the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) signaling pathways [72].…”